SALINAS, Calif.--(BUSINESS WIRE)--Next Pharmaceuticals announced today the results of a clinical study on Nexrutine, conducted at The LaValle Metabolic Institute in Cincinnati, Ohio. Nexrutine is a proprietary blend of natural ingredients developed to address general aches and pains associated with physical activity and over-exertion. Out of the 401 participants 369 (92%) reported Nexrutine provided pain relief and 373 (93%) reported improvement in their overall condition. Three hundred sixty one (90%) reported Nexrutine helped provide a restful sleep.
